Allworth Financial’s Accelerate Diagnostics AXDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-10,400
| Closed | -$5.67K | – | 4592 |
|
|
2025
Q1 | $5.67K | Hold |
10,400
| – | – | ﹤0.01% | 2689 |
|
|
2024
Q4 | $11.6K | Hold |
10,400
| – | – | ﹤0.01% | 2374 |
|
|
2024
Q3 | $17.8K | Hold |
10,400
| – | – | ﹤0.01% | 1994 |
|
|
2024
Q2 | $11.6K | Hold |
10,400
| – | – | ﹤0.01% | 2166 |
|
|
2024
Q1 | $10.3K | Buy |
10,400
+10,000
| +2,500% | +$15.8K | ﹤0.01% | 2097 |
|
|
2023
Q4 | $1.57K | Sell |
400
-15,000
| -97% | -$79.3K | ﹤0.01% | 2781 |
|
|
2023
Q3 | $88.5K | Hold |
15,400
| – | – | ﹤0.01% | 925 |
|
|
2023
Q2 | $125K | Hold |
15,400
| – | – | ﹤0.01% | 818 |
|
|
2023
Q1 | $108K | Buy |
+15,400
| New | +$92.6K | ﹤0.01% | 832 |
|
|
2022
Q4 | – | Sell |
-15,400
| Closed | -$234K | – | 3015 |
|
|
2022
Q3 | $234K | Hold |
15,400
| – | – | ﹤0.01% | 560 |
|
|
2022
Q2 | $153K | Buy |
15,400
+5,200
| +51% | +$45.9K | ﹤0.01% | 610 |
|
|
2022
Q1 | $147K | Buy |
10,200
+5,200
| +104% | +$148K | ﹤0.01% | 623 |
|
|
2021
Q4 | $261K | Buy |
5,000
+1,000
| +25% | +$55.7K | ﹤0.01% | 477 |
|
|
2021
Q3 | $233K | Hold |
4,000
| – | – | ﹤0.01% | 448 |
|
|
2021
Q2 | $322K | Hold |
4,000
| – | – | 0.01% | 309 |
|
|
2021
Q1 | $333K | Buy |
4,000
+900
| +29% | +$91.3K | 0.01% | 284 |
|
|
2020
Q4 | $235K | Buy |
+3,100
| New | +$278K | 0.01% | 267 |
|
Other funds holding AXDX
Allworth Financial's AXDX Position: Q2 2025 in Review
Allworth Financial sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 10,400 shares — an estimated $5.67K sold.
Allworth Financial first reported a position in AXDX in Q4 2020 and held it in 17 quarters. The position peaked at $333K in Q1 2021. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.
- Allworth Financial reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
- Allworth Financial sold 10,400 Accelerate Diagnostics shares in Q2 2025, an estimated $5.67K.
- Allworth Financial first reported a position in Accelerate Diagnostics in Q4 2020 and held it in 17 quarters.
- Allworth Financial's Accelerate Diagnostics position peaked at $333K in Q1 2021.
- 3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.
Based on Allworth Financial's 13F filing for Q2 2025, filed 7 Aug 2025.